Licensing was Aclaris Therapeutics’s largest product and service line in fiscal 2025, bringing in $5.95M of $13.78M (43%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Licensing | $25.10M | $28.21M | $16.18M | $5.95M | |||||
| Dermatology Therapeutics | — | — | $16.18M | $5.95M | |||||
| Contract Research | $4.40M | $3.04M | $2.54M | $1.87M | |||||
| Other | $257.00K | — | — | — | |||||
| Other Revenue | — | — | — | — | |||||
| Total | $29.75M | $31.25M | $34.90M | $13.78M |
Aclaris Therapeutics brought in $13.78M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 60.5% from $34.90M in fiscal 2024. Licensing was the largest at $5.95M (43.2%), ahead of Dermatology Therapeutics at $5.95M (43.2%) and Contract Research at $1.87M (13.6%).
Compared with fiscal 2024, every line above 2% of revenue shrank. Contract Research held up best, down 26.3% to $1.87M, and Dermatology Therapeutics fell the most, down 63.2% to $5.95M.
Aclaris Therapeutics began breaking out Dermatology Therapeutics in fiscal 2024, when it brought in $16.18M. Aclaris Therapeutics stopped reporting Other as a separate line after fiscal 2022, when it brought in $257.00K.
Aclaris Therapeutics (ACRS) reports its revenue by product and service. In fiscal 2025, Licensing was its largest product and service line, bringing in $5.95M (43.2% of the total), followed by Dermatology Therapeutics at $5.95M (43.2%).
Licensing was Aclaris Therapeutics' largest product and service line in fiscal 2025, bringing in $5.95M, or 43.2% of the $13.78M total across its three product and service lines.
Every figure comes from Aclaris Therapeutics' annual financial filings, as reported. Each line keeps the name Aclaris Therapeutics gives it, and years follow its fiscal calendar.
Aclaris Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.